|
| |
|
| Male sex, (%) | 64 (52.0) |
| Age, years, (range) | (15-92) |
| Age at onset, (range) | (0-89) |
| Age at onset, (%) | |
| <5 years | 15 (12.2) |
| 5-11 years | 22 (17.9) |
| 12-20 years | 42 (34.1) |
| 21-45 years | 23 (18.7) |
| 46-59 years | 13 (10.6) |
| ≥60 years | 8 (6.5) |
| Epilepsy duration, years, (range) | (0-59) |
| Type of epilepsy, (%) | |
| Focal | 78 (63.4) |
| Generalized | 45 (36.6) |
| Epilepsy syndrome and etiology, (%) | |
| Focal epilepsy | 78 (63.4) |
| Unknown etiology | 28 (22.8) |
| Structural etiology | 50 (40.7) |
| Genetic generalized epilepsy | 45 (36.6) |
| Other | 2 (1.6) |
| Juvenile myoclonic epilepsy | 8 (6.5) |
| GGE with GTCS | 32 (26.0) |
| Juvenile absence epilepsy | 2 (1.6) |
| Childhood absence epilepsy | 1 (0.8) |
| Drug-resistant epilepsy, (%) | 63 (51.2) |
| Tonic-clonic seizure types, (%) | |
| GTCS | 45 (36.6) |
| FBTCS | 78 (63.4) |
| Number of FBGTS/GTCS in the 3 months prior to inclusion (median) | 1 (IQR: 0-3) (range: 0-30) |
| Monthly FBTCS/GTCS frequency | 0.33 (IQR: 0-1) (range: 0-10) |
| Number of FBTCS/GTCS in the last year prior to inclusion (median) | 2 (IQR: 0-6) (range: 0-120) |
| Monthly FBTCS/GTCS frequency | 0.17 (IQR: 0-0.5) (range: 0-10) |
| Other seizure types in the 3 months prior to inclusion, (%) | 70 (56.9) |
| Focal seizures without impaired awareness | 9 (7.3) |
| Focal seizures with impaired awareness | 37 (30.1) |
| Myoclonic | 17 (13.8) |
| Absences | 15 (12.2) |
| Other | 8 (6.5) |
| Median seizure frequency per month in the 3 months prior to inclusion (all seizure types) | 1 (IQR: 0-4) (range: 0-64) |
| Median seizure frequency per month in 1 year prior to inclusion (all seizure types) | 0.5 (IQR: 0.1-2.7) (range: 0-42) |
| BRV dose (mg) | 75 (IQR:50-100) (range:25-300) |
| Titration phase, (%) | 44 (35.8) |
|
